POLYMORPHIC COMPOUNDS AND USES THEREOF
The present invention provides freebase and salt forms, and compositions and methods thereof, useful for treating various conditions in which the aryl hydrocarbon receptor (AHR) is implicated, by the administration of small molecule therapeutics which act as inhibitors of AHR.
1 . A solid form of Compound 2:
wherein about 1≤x≤about 2.
2 . The compound according to claim 1 , wherein said compound is crystalline.
3 . The compound according to claim 1 , wherein said compound is a crystalline solid substantially free of amorphous compound 2.
4 . The compound according to claim 1 , wherein said compound is substantially free of impurities.
5 . The compound according to claim 1 , having one or more peaks in its XRPD selected from those at about 5.3, about 11.3 and about 16.0 degrees 2-theta.
6 . The compound according to claim 5 , having at least two peaks in its XRPD selected from those at about 5.3, about 11.3 and about 16.0 degrees 2-theta.
7 . The compound according to claim 6 , wherein said compound is of Form A, and wherein x is about 2.
8 . The compound according to claim 1 , having an XRPD substantially similar to that depicted in FIG. 9 .
9 . A composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier or excipient.
10 . A method of inhibiting AHR in a patient in need thereof, comprising administering to said patient the compound according to claim 1 or a composition thereof.
11 . A method of inhibiting AHR in a biological sample, comprising contacting the biological sample with the compound according to claim 1 or a composition thereof.
12 . A method for treating an AHR-mediated disorder in a patient in need thereof, comprising administering to said patient the compound according to claim 1 or a composition thereof.
13 . The method according to claim 12 , wherein the AHR-mediated disorder is a cancer.
14 . The method according to claim 12 , wherein the AHR-mediated disorder is an inflammatory disorder.
15 . The method according to claim 12 , wherein the compound or composition thereof is administered orally.
16 . The method according to claim 12 , wherein the compound or composition thereof is administered in a range of 0.01-100 mg/kg body weight of the patient.
17 . The method according to claim 12 , further comprising administering to the patient an additional therapeutic agent.
18 . A compound selected from:
Compound A:
of Form A, Form B or Form C;
Compound 1:
of Form A or Form B;
Compound 3:
of Form A or Form B;
Compound 4:
of Form A;
Compound 5:
of Form A;
Compound 6:
of Form A or Form B, wherein about 1≤x≤about 2; or
Compound 7:
of Form A, wherein about 1≤x≤about 2.
19 . A pharmaceutically acceptable composition comprising a compound according to claim 18 , and a pharmaceutically acceptable carrier, excipient, or vehicle.
20 . A method for treating an AHR-mediated disorder in a patient in need thereof, comprising administering to said patient the compound according to claim 18 or a composition thereof.
21 . The method according to claim 20 , wherein the AHR-mediated disorder is a cancer or an inflammatory disorder.
22 . The method according to claim 20 , wherein the compound or composition thereof is administered orally.
23 . The method according to claim 20 , wherein the compound or composition thereof is administered in a range of 0.01-100 mg/kg body weight of the patient.
24 . The method according to claim 20 , further comprising administering to the patient an additional therapeutic agent.
25 . A method for preparing a salt compound of the formula X:
comprising steps of:
combining A:
with an acid and optionally a solvent under conditions for forming a salt compound of formula X.
26 . The method of claim 25 , wherein:
(a) the suitable acid is methanesulfonic acid thereby forming a mesylate salt of compound A and optionally crystallizing said mesylate salt to form Form A or Form B;
(b) the suitable acid is ethanesulfonic acid thereby forming a esylate salt of compound A and optionally crystallizing said esylate salt to form Form A or Form B;
(c) the suitable acid is napthalenesulfonic acid thereby forming a napsylate salt of compound A an optionally crystallizing said napsylate salt to form Form A;
(d) the suitable acid is tartaric acid thereby forming a tartrate salt of compound A and optionally crystallizing said tartrate salt to form Form A or Form B;
(e) the suitable acid is oxalic acid thereby forming an oxalate salt of compound A and optionally crystallizing said oxalate salt to form Form A; or
(f) the suitable acid is ethanedisulfonic acid thereby forming an edisylate salt of compound A and optionally crystallizing said edisylate salt to form Form A.